LSM5 (LSM5 Homolog, U6 Small Nuclear RNA And MRNA Degradation Associated)

Experimental validation showed LSM5 is overexpressed in NPC tissues, correlating with poorer prognosis, and its down-regulation inhibits cell proliferation and migration. Thus, LSM5 is identified as a new adverse biomarker in NPC, with implications for targeted therapy and prognosis improvement.

LSM5 knockdown inhibited the proliferation and facilitated the apoptosis of colon cancer cells by upregulating p53, CDKN1A and TNFRSF10B.

The expression of LSMs was upregulated in GC tissues and most of LSMs were negatively correlated with overall survival of GC patients with 5-fluorouracil (5-FU) treatment...Moreover, both TIMER and IHC revealed that a lower expression of LSM5 and LSM8 was correlated with high infiltration of T cells, regulatory T cells, B cells, macrophages, and neutrophils. Our study systematically investigated the expression pattern and biological features of LSM family members in GC, and identified LSM5 and LSM8 as potential biomarkers in GC with 5-FU chemotherapy.